Session » 5T092: RA – Treatments IV: Novel Therapy & Predicting Response (2768–2773)

Date: Tuesday, November 12, 2019

Time: 2:30PM-4:00PM

Meeting: 2019 ACR/ARP Annual Meeting

2:30PM-4:00PM: Abstract Number: 2771

A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate

2:30PM-4:00PM: Abstract Number: 2768

Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2772

Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet

2:30PM-4:00PM: Abstract Number: 2773

Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier

2:30PM-4:00PM: Abstract Number: 2769

The Pre-Treatment Gut Microbiome Predicts Early Response to Methotrexate in Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 2770

Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission

« View all sessions from this meeting